Quest Diagnostics has licensed the rights to biomarkers developed by Matrix-Bio in an effort to create a clinical test for recurrent breast cancer. Matrix-Bio Founder and CSO Dan Raftery called the move "a big step toward our goal to make improved and more efficient testing methods for diagnosing many forms of cancer available to physicians and patients."

Related Summaries